Small-Molecule APIs

The contract renewal allows AMRI to continue to provide medicinal chemistry and ADME services for advancing drug discovery programs in neurotherapeutics.

CMOs/CDMOs that are easy to work with, have demonstrated performance track records, and plan for the future are preferred.

Assessing potential formulation and manufacturing issues in early development phases can improve a drug’s chances for success.

Highly complex APIs developed to treat rare and orphan diseases present big technical questions for contract developers.

Cambrex invests in development and laboratory facilities and adds staff.

Avista Pharma's strengthens early phase drug development offerings with acquisition of Solid Form Solutions.

A ceremony was held at Cambrex’s Karlskoga facility to mark the commencement of a long-term manufacturing agreement with AstraZeneca for a key intermediate.

FDA looks to achieve near-record level of new drug approvals following slowdown in 2016.

MJR PharmJet's MicroJet Reactor technology is a continuous process for producing nanoparticles with tightly controlled particle size and particle size distribution.

For many processes involving hazardous chemistry, running in flow mode has safety and economic advantages.

Avista Pharma Solutions facility and equipment upgrades at its Longmont, Colorado facility support processing of potent compounds.

CordenPharma will expand development capacity for small molecules, peptides, and carbohydrates at its Liestal, Switzerland site

Additional reactor capacity and a wastewater processing plant increase API manufacturing capacity at the Cambrex site in Kalskoga, Sweden.

BASF will build a new specialty amines plant at its existing wholly owned site in Nanjing Chemical Industry Park in China.

Ajinomoto Althea opens manufacturing suites in new high potency and antibody drug conjugate commercial facility.

Drug repurposing, repositioning, and rescue can be faster, cheaper, and target more diseases than traditional drug discovery approaches.

Innovative new technologies released over the past several months seek to enhance bio/pharmaceutical development and manufacturing. 

Featuring software, parallel automated reactors, and other tools designed to facilitate design of experiments, development of the design space, and better process understanding and control, the Hyderabad facility came online on July 20

Industrial-scale continuous API manufacturing may offer cost and safety benefits.

As pharma models changed during the past 40 years, contract manufacturing capacity and services evolved to meet demand.

SK Biotek plans to operate the Swords, Ireland API manufacturing facility as a contract development and manufacturing site.

Cambrex announces expansions of its North Carolina API pilot plant and Kalskoga, Sweden large-scale manufacturing facility.

Efficient synthesis of complex cannabinoids is possible while avoiding marijuana cultivation.

Spectrum Pharmacy Products opens pharmacy institute for training in pharmaceutical compounding.

Advances in chemical synthesis are enabling greener, more cost-efficient processes for API manufacturing.

Advances in process analytical technology have been achieved, but significant challenges remain.

New website allows access to research quantities of commercial-grade ligands and catalysts.

As of mid-December, less than half the number of new drug approvals were issued by FDA in 2016 compared with 2015.

Patheon adds API manufacturing capacity with acquisition of Roche’s Florence, SC facility.

he guidance addresses the good manufacturing practice for managing quality in APIs.